The notion that EGFR mutations are correlated with high PD-L1 expression has since been challenged, and it has been suggested that EGFR mutations are associated with low PD-L1 and low tumor immunogenicity, possibly explaining the clinical outcomes [49]. This evidence concerns the gene CD274 and neoplasm.